Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors.
about
Phosphoproteomics: new insights into cellular signalingTranslocation of human ribosomal protein S3 to sites of DNA damage is dependant on ERK-mediated phosphorylation following genotoxic stressActivity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioningActivation of protein synthesis in cardiomyocytes by the hypertrophic agent phenylephrine requires the activation of ERK and involves phosphorylation of tuberous sclerosis complex 2 (TSC2)The mTOR signalling pathway in human cancerThe TSC1-TSC2 complex: a molecular switchboard controlling cell growthMethodologies for characterizing phosphoproteins by mass spectrometryTargeting the intragraft microenvironment and the development of chronic allograft rejectionNutrient regulation of the mTOR complex 1 signaling pathwayDual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancerRAS oncogenes: weaving a tumorigenic webRSK phosphorylates SOS1 creating 14-3-3-docking sites and negatively regulating MAPK activationProteomics analysis of protein kinases by target class-selective prefractionation and tandem mass spectrometrymiRNA Alterations Modify Kinase Activation In The IGF-1 Pathway And Correlate With Colorectal Cancer Stage And Progression In PatientsA small-molecule inhibitor of T. gondii motility induces the posttranslational modification of myosin light chain-1 and inhibits myosin motor activityMechanism for activation of the growth factor-activated AGC kinases by turn motif phosphorylationThe role of the Birt-Hogg-Dubé protein in mTOR activation and renal tumorigenesisRegulation of the mTOR complex 1 pathway by nutrients, growth factors, and stressInhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancerPI3K and cancer: lessons, challenges and opportunitiesCurrent phase II clinical data for ridaforolimus in cancer.Quantification of gel-separated proteins and their phosphorylation sites by LC-MS using unlabeled internal standards: analysis of phosphoprotein dynamics in a B cell lymphoma cell line.Systematic analysis of the epidermal growth factor receptor by mass spectrometry reveals stimulation-dependent multisite phosphorylation.Functional characterisation of the TSC1-TSC2 complex to assess multiple TSC2 variants identified in single families affected by tuberous sclerosis complex.Novel Ser/Thr protein phosphatase 5 (PP5) regulated targets during DNA damage identified by proteomics analysis.Intercellular transfer of proteins as identified by stable isotope labeling of amino acids in cell culture.Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML.Phosphatidic acid mediates activation of mTORC1 through the ERK signaling pathway.RAS Interaction with PI3K: More Than Just Another Effector PathwayFyn promotes phosphorylation of collapsin response mediator protein 1 at tyrosine 504, a novel, isoform-specific regulatory site.Label-free relative quantification of co-eluting isobaric phosphopeptides of insulin receptor substrate-1 by HPLC-ESI-MS/MS.Assaying pharmacodynamic endpoints with targeted therapy: flavopiridol and 17AAG induced dephosphorylation of histone H1.5 in acute myeloid leukemia.Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways.Peptide sharing between influenza A H1N1 hemagglutinin and human axon guidance proteins.Ultrasensitive and absolute quantification of the phosphoinositide 3-kinase/Akt signal transduction pathway by mass spectrometry.Identification of SLAMF3 (CD229) as an inhibitor of hepatocellular carcinoma cell proliferation and tumour progression.Clinical and technical phosphoproteomic research.Overexpression of PAK1 promotes cell survival in inflammatory bowel diseases and colitis-associated cancer.Discovery of the serum biomarker proteins in severe preeclampsia by proteomic analysisTechnical phosphoproteomic and bioinformatic tools useful in cancer research.
P2860
Q21184157-2D3BAB3A-BB6E-40C8-B3B2-61897161E462Q24309217-75ABFE70-E2DC-4B59-8078-48BEB3F13E50Q24320102-685C08D5-F8FC-49A5-B32A-0482DBEC2947Q24534560-A246E2D7-CCF2-4B84-A68A-9405ECA40439Q24627306-110223EF-AA96-4E40-9EF4-8901A2780E86Q24645204-FCFCBD19-340B-4713-9C95-A3B359195DE3Q24683926-17B13982-66A9-4336-A264-16198941412BQ26852762-80847634-A467-4432-BD5F-94945E3966AFQ27027823-46C77E37-84EC-41D3-ABE7-07670282FD47Q27324821-556E5380-83F3-451F-9B41-543AF72DE926Q28250360-D1336270-7457-42F8-9453-7F586CF5A47EQ28271724-57E0B23F-9664-4BC6-8D1D-43FD0ECAE49DQ28280900-0A6602B8-6389-482E-93E0-567029F1454BQ28392422-9AB41925-CEB1-4CEA-9431-C5DC975C1BB5Q28472485-45BF9B90-5CDC-41E9-BBCA-10877D7DCB22Q28568275-0D969AE1-1BD5-4C0B-93E2-F3800CD9D9A0Q28590041-AD0CE994-7FE1-49CB-8D43-163F73433DDCQ29614493-BB06566A-079B-4D8B-876D-B79225ADAA9CQ29618030-0F2818BF-6324-4710-81B3-B6359A5A3DA3Q30080017-560DA470-7C7E-42BA-9CDA-0609018291EDQ30662689-F6B0574F-E7D3-483B-8ACF-71A8B35BF5EDQ31170961-BD639965-3A18-4F69-9BDF-9B05969F196CQ33215314-1BF0B4F5-F8D2-404B-A1FD-ABB74D3BB023Q33321312-0975F3A0-8880-4DC3-942A-E6337335B847Q33639959-D22175E4-B8C8-4FB4-981F-DB6E181F6EC3Q33673605-4167D579-58A9-40C2-90BD-595EA226721AQ33840360-0A6B0864-9598-46D3-8D5A-936341CFABC1Q34085728-DC7D6DB7-9B2F-4A33-AA78-1912F81C8332Q34202692-D7B12E83-A4EC-4A21-BE20-98CCE86FD56CQ34344601-CAAF92F7-9F89-4B80-BD12-DDEFAB6BBBCCQ34369237-3986BA2E-65B4-4133-B2B3-3EE8AB13489EQ34493326-9E390570-0E65-4280-B150-8D967934F044Q34562010-E783042C-DB36-4814-9930-69351C5C6CEDQ34573339-338AB34C-F1E0-489F-B5A1-33DE633CF343Q34694707-CBA55C90-0E81-4C78-9717-68628EE928B5Q35077803-6E972EE3-55ED-4F3D-8A30-A8406B40EAF7Q35081756-C3200E15-A345-4B02-8F06-EC9BCD07B236Q35136001-78921F9A-E0B0-43AF-B8EA-6C36873BCF92Q35171868-63284D1B-1BAF-4B2F-986E-23F288968C1DQ35373413-F050279D-C87A-4AC7-80BE-AEAAF67E8CFF
P2860
Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Quantitative phosphorylation p ...... s sclerosis tumor suppressors.
@ast
Quantitative phosphorylation p ...... s sclerosis tumor suppressors.
@en
type
label
Quantitative phosphorylation p ...... s sclerosis tumor suppressors.
@ast
Quantitative phosphorylation p ...... s sclerosis tumor suppressors.
@en
prefLabel
Quantitative phosphorylation p ...... s sclerosis tumor suppressors.
@ast
Quantitative phosphorylation p ...... s sclerosis tumor suppressors.
@en
P2860
P50
P356
P1476
Quantitative phosphorylation p ...... us sclerosis tumor suppressors
@en
P2093
Bryan A Ballif
John Blenis
P2860
P304
P356
10.1073/PNAS.0409143102
P407
P577
2005-01-12T00:00:00Z